Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Skybiotech Healthcare EBITDA Margin % Related Terms
Skybiotech Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Skybiotech Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:512036 vs MMM, HON: EBITDA Margin % Comparison
For the Conglomerates subindustry, Skybiotech Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Skybiotech Healthcare EBITDA Margin % vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Skybiotech Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Skybiotech Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Skybiotech Healthcare (BOM:512036) has a EBITDA Margin % of -39.73% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Skybiotech Healthcare and its competitors. According to the industry distribution chart, Skybiotech Healthcare ranks #495 out of 541 companies in the Conglomerates industry, placing it in the top 91.5%.
Is Skybiotech Healthcare's EBITDA Margin % too high?
Skybiotech Healthcare's current EBITDA Margin % is -39.73%. Based on the distribution chart, Skybiotech Healthcare ranks #495 out of 541 companies in the Conglomerates industry, which is in the bottom quartile relative to peers. Overall, Skybiotech Healthcare has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Skybiotech Healthcare's EBITDA Margin % compare to MMM and HON?
According to the Conglomerates industry distribution chart, Skybiotech Healthcare ranks #495 out of 541 companies for EBITDA Margin %. This places Skybiotech Healthcare in the lower half of its industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Conglomerates company?
The median EBITDA Margin % among Conglomerates companies is 12.44, based on 541 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Skybiotech Healthcare and its competitors. For the Conglomerates industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Skybiotech Healthcare's current EBITDA Margin % is -39.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skybiotech Healthcare stock overvalued right now?
Skybiotech Healthcare (BOM:512036) has a current EBITDA Margin % of -39.73%. The current EBITDA Margin % is -39.73%. Skybiotech Healthcare's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Skybiotech Healthcare (BOM:512036), the current EBITDA Margin % is -39.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Skybiotech Healthcare Ltd, formerly Kapil Cotex Ltd is engaged in textiles and allied products, including dyeing, printing, spinning, weaving, and manufacturing fabrics from raw cotton. During the year under review, the company has not generated any revenue from its core business activities. Instead, it earned income from consultancy services for foreign clients and from investments in shares, generating capital gains and dividends. The company's current revenue mainly comes from these non-core activities rather than textile manufacturing.
23GF Score
Get the complete analysis for BOM:512036
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:512036 has been successfully added to your 
